In the biopharmaceutical industry, manufacturers have had to grapple with supply chain disruptions, rapid changes to the market, and geopolitical instability for the past several years. With these challenges expected to continue in 2026, biopharma executives are looking for sources of confidence that can provide more security and guaranteed gains for their manufacturing pipeline.
Digital twins have emerged as a valuable tool to help biopharma manufacturers combat uncertainty. Factory digital twins in particular have helped companies derisk their manufacturing planning with unique features that model and measure the impact of various investment possibilities. According to the National Science Foundation, digital twins “save time, reduce risk, and support smarter decisions.” Software like VirtECS has helped biopharma clients select smart and safe investment options through two primary features: process modeling and scenario analysis.
Process Modeling
One of the core functions of a factory digital twin, such as VirtECS, is creating a virtual model of a manufacturing site’s unique set of processes. This virtual model, which includes details like equipment specifications and supply chain restrictions, uses an advanced algorithm to evaluate how the plant’s performance will change when different investments are added to the model. For biopharma executives looking for quantitative reassurance and accuracy in their investments, these capabilities are key for ensuring ROI for investors. As a recent article from Samsung Biologics states, “As the biopharma industry embraces smarter technologies, digital twins are emerging as a powerful tool to improve process precision.”
With their detailed plant model, site planners can adjust the details of their investments to determine a path forward that improves performance without impacting other deadlines. For example, if a new product will be added or the company decides to expand the facility to add capacity, a digital twin can help evaluate each option to find a plant configuration that will meet output requirements. “Having a VirtECS process model allowed our client to look at different potential plant configurations,” said Steve Harding, President of APCI. “This let them maximize the value of each new investment they made.”
Additionally, a digital twin process model can identify operational disruptions that changes to the manufacturing facility are likely to produce. We often see that investments and advancements in upstream manufacturing cause unforeseen bottlenecks downstream. In past projects for biopharma facilities, VirtECS has identified and resolved bottlenecks that would have caused lengthy delays or compliance issues, and ultimately prevented increased costs. As a result, the sites have been able to select more optimal plans that avoid bottlenecks before they begin.
Scenario Analysis
The factory digital twin can also offer scenario analysis capabilities, which helps biopharma manufacturers evaluate the profitability of proposed investments and process changes. Once biopharma planners have adjusted their process model and identified an optimized plan that includes their desired changes, they can then use scenario analysis to test whether the model’s resulting product output will generate enough value to cover the investment.
VirtECS scenario analysis works by measuring how much more (or less) output can be produced under the given process model. It can account for reductions to changeover time, maintenance costs, equipment effectiveness, and many other factors that may affect total profitability. With this data, biopharma companies can ensure that their investment will produce a suitable return before making any irreversible and costly physical changes. Planners can also compare the results of several different models with different investment options to decide which is the best use of available capital with the highest ROI.
With manufacturers facing rising costs across the board, some may also look to factory digital twins to reduce their total investments and minimize their financial risks. Some biopharma companies have used a factory digital twin to uncover untapped capacity in their existing site, negating the need for any added investment. McKinsey recently cited a case study that saw a manufacturer using a digital twin to analyze their current facility and relocate it on 50% less real estate without losing functionality, thereby significantly reducing their total operating costs and improving profitability.
For one VirtECS client, the goal was to trim down the investment needed upfront without sacrificing any capacity. They input their proposed investments, which included new production equipment, into the VirtECS process model and used scenario analysis to determine the resulting impact on production. Ultimately, this pharmaceutical company was able to reduce their necessary capital investment by $300 million by demonstrating areas where more equipment did not benefit throughput, according to their senior resource planning manager. You can read more about how VirtECS has helped biopharma companies improve their investment decision-making and strategically increase capacity in the case studies in our overview guide, available for download here.
